Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes

Citations

WEB OF SCIENCE

27
Citations

SCOPUS

31

초록

Precision medicine is a scientific and medical practice for personalized therapy based on patients' individual genetic, environmental, and lifestyle characteristics. Pharmacogenetics and pharmacogenomics are also rapidly developing and expanding as a key element of precision medicine, in which the association between individual genetic variabilities and drug disposition and therapeutic responses are investigated. Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by hyperglycemia mainly associated with insulin resistance, with the risk of clinically important cardiovascular, neurological, and renal complications. The latest consensus report from the American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) on the management of T2D recommends preferential use of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and some dipeptidyl peptidase-4 (DPP-4) inhibitors after initial metformin monotherapy for diabetic patients with established atherosclerotic cardiovascular or chronic kidney disease, and with risk of hypoglycemia or body weight-related problems. In this review article, we summarized current progress on pharmacogenetics of newer second-line antidiabetic medications in clinical practices and discussed their therapeutic implications for precision medicine in T2D management. Several biomarkers associated with drug responses have been identified from extensive clinical pharmacogenetic studies, and functional variations in these genes have been shown to significantly affect drug-related glycemic control, adverse reactions, and risk of diabetic complications. More comprehensive pharmacogenetic research in various clinical settings will clarify the therapeutic implications of these genes, which may be useful tools for precision medicine in the treatment and prevention of T2D and its complications.

키워드

pharmacogenetics; precision medicine; personalized medicine; type 2 diabetes; second-line antidiabetic medications; DPP-4 inhibitors; GLP-1 receptor agonists; SGLT2 inhibitors; GLUCAGON-LIKE PEPTIDE-1; INADEQUATE GLYCEMIC CONTROL; GLUCOSE COTRANSPORTER 2; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; CANNABINOID RECEPTOR GENE; GENOME-WIDE ASSOCIATION; EXENATIDE SYNTHETIC EXENDIN-4; SELECTIVE SGLT2 INHIBITOR; FAMILIAL RENAL GLUCOSURIA; FATTY LIVER-DISEASE
제목
Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes
저자
Heo, Chan Uk; Choi, Chang-Ik
DOI
10.3390/jcm8030393
발행일
2019-03-21
유형
Review
저널명
JOURNAL OF CLINICAL MEDICINE
권
8
호
3